Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

SummaryThe blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances. BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS. The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB. In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function. Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain. However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases. Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication. Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.

[1]  W. Löscher,et al.  Immunohistochemical Localization of P-glycoprotein in Rat Brain and Detection of Its Increased Expression by Seizures Are Sensitive to Fixation and Staining Variables , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  W. Löscher,et al.  Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures , 2004, Neuroscience.

[3]  D. Horrobin,et al.  Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. , 2004, The international journal of neuropsychopharmacology.

[4]  W. Löscher,et al.  Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats , 2004, Neuroreport.

[5]  W. Löscher,et al.  The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions , 2004, Nature Medicine.

[6]  K. Yamada,et al.  St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[7]  S. A. Thomas,et al.  Anti-HIV drug distribution to the central nervous system. , 2004, Current pharmaceutical design.

[8]  S. Cisternino,et al.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. , 2004, Cancer research.

[9]  J. C. Baayen,et al.  Expression and Cellular Distribution of Multidrug Resistance–related Proteins in the Hippocampus of Patients with Mesial Temporal Lobe Epilepsy , 2004, Epilepsia.

[10]  R. Kerwin,et al.  Do antidepressants regulate how cortisol affects the brain? , 2004, Psychoneuroendocrinology.

[11]  D. Begley,et al.  ABC transporters and the blood-brain barrier. , 2004, Current pharmaceutical design.

[12]  G. Fricker,et al.  Modulation of Drug Transporters at the Blood-Brain Barrier , 2004, Pharmacology.

[13]  A. M. George,et al.  The ABC transporter structure and mechanism: perspectives on recent research , 2004, Cellular and Molecular Life Sciences CMLS.

[14]  C. Tirolo,et al.  Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Löscher,et al.  Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats , 2004, Epilepsy Research.

[16]  C. L. Graff,et al.  Drug transport at the blood-brain barrier and the choroid plexus. , 2004, Current drug metabolism.

[17]  S. Cole,et al.  The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.

[18]  W. Löscher,et al.  Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats , 2004, Epilepsy Research.

[19]  C. L. Graff,et al.  Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.

[20]  A. Walmsley,et al.  Structure and function of efflux pumps that confer resistance to drugs. , 2003, The Biochemical journal.

[21]  Y. Sheline,et al.  Psychiatric comorbidity, health, and function in epilepsy , 2003, Epilepsy & Behavior.

[22]  W. Löscher,et al.  Brain Access and Anticonvulsant Efficacy of Carbamazepine, Lamotrigine, and Felbamate in ABCC2/MRP2‐Deficient TR− Rats , 2003, Epilepsia.

[23]  W. Pardridge,et al.  P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. , 2003, Neuroreport.

[24]  B. Dijkmans,et al.  Multidrug resistance proteins in rheumatoid arthritis, role in disease‐modifying antirheumatic drug efficacy and inflammatory processes: an overview , 2003, Scandinavian journal of rheumatology.

[25]  S. Choudhuri,et al.  Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  M. Fromm,et al.  Importance of P‐glycoprotein for drug disposition in humans , 2003, European journal of clinical investigation.

[27]  L. Martinian,et al.  Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory Epilepsy , 2003, Epilepsia.

[28]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[29]  F. Holsboer,et al.  Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption , 2003, Biological Psychiatry.

[30]  P. L. Golden,et al.  Blood-brain barrier efflux transport. , 2003, Journal of pharmaceutical sciences.

[31]  R. Kim Drug transporters in HIV Therapy. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[32]  W. Löscher,et al.  Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[33]  H. Galla,et al.  Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier , 2003, Brain Research.

[34]  E. Aronica,et al.  Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors , 2003, Neuroscience.

[35]  D. Janigro,et al.  Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. , 2003, Current drug targets.

[36]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[37]  S. Sisodiya Mechanisms of antiepileptic drug resistance , 2003, Current opinion in neurology.

[38]  Christian E Elger,et al.  A novel mechanism underlying drug resistance in chronic epilepsy , 2003, Annals of neurology.

[39]  W. Haefeli,et al.  Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.

[40]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[41]  N. Shaik,et al.  Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.

[42]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[43]  D. Binder Mechanisms of drug resistance in epilepsy: lessons from oncology. London, United Kingdom, 13-15 March 2001. Symposium proceedings. , 2002, Novartis Foundation symposium.

[44]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[45]  Armin Buschauer,et al.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.

[46]  Wolfgang Löscher,et al.  Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy , 2002, Epilepsy Research.

[47]  W. Löscher,et al.  Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. , 2002, European journal of pharmacology.

[48]  M. Vore,et al.  Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition , 2002, Journal of Pharmacology and Experimental Therapeutics.

[49]  J. Hirrlinger,et al.  Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones , 2002, Journal of neurochemistry.

[50]  E. Aronica,et al.  Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance , 2002, The Journal of Neuroscience.

[51]  P. McNamara,et al.  GF120918, a P-Glycoprotein Modulator, Increases the Concentration of Unbound Amprenavir in the Central Nervous System in Rats , 2002, Antimicrobial Agents and Chemotherapy.

[52]  R. Béliveau,et al.  Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.

[53]  A. Neyfakh Mystery of multidrug transporters: the answer can be simple , 2002, Molecular microbiology.

[54]  Wolfgang Löscher,et al.  Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. , 2002, The Journal of pharmacology and experimental therapeutics.

[55]  R. Upton,et al.  Theoretical Aspects of P-glycoprotein Mediated Drug Efflux on the Distribution Volume of Anaesthetic-related Drugs in the Brain , 2002, Anaesthesia and intensive care.

[56]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.

[57]  W. Löscher Current status and future directions in the pharmacotherapy of epilepsy. , 2002, Trends in pharmacological sciences.

[58]  N. Russell,et al.  P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype , 2002, Leukemia & lymphoma.

[59]  J. Drewe,et al.  By-passing of P-glycoprotein Using Immunoliposomes , 2002, Journal of drug targeting.

[60]  M. Mayberg,et al.  Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy , 2001, Epilepsia.

[61]  R. Bendayan,et al.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.

[62]  W. Löscher,et al.  P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain , 2001, Neuroreport.

[63]  W. Löscher,et al.  Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain , 2001, Neuroreport.

[64]  A. Sartorelli,et al.  Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. , 2001, Biochemical and biophysical research communications.

[65]  T. Druley,et al.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.

[66]  D. Breimer,et al.  Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier , 2001, AIDS.

[67]  G. Pasternak,et al.  Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs , 2001, Nature Neuroscience.

[68]  U. Brinkmann,et al.  ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.

[69]  M. Thom,et al.  Multidrug-resistance protein 1 in focal cortical dysplasia , 2001, The Lancet.

[70]  W. Elmquist,et al.  Microdialysis in the study of drug transporters in the CNS. , 2000, Advanced drug delivery reviews.

[71]  J. Drewe,et al.  Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. , 2000, Molecular pharmacology.

[72]  W Vaalburg,et al.  The blood-brain barrier and oncology: new insights into function and modulation. , 2000, Cancer treatment reviews.

[73]  Donald W. Miller,et al.  Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells , 2000, Brain Research.

[74]  S. R. Harris,et al.  The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[75]  L. Ratner,et al.  Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.

[76]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[77]  G. Pollack,et al.  Morphine Antinociception Is Enhanced in mdr1a Gene-Deficient Mice , 2000, Pharmaceutical Research.

[78]  J. Laplanche,et al.  Functional expression of p‐glycoprotein and multidrug resistance‐associated protein (mrp1) in primary cultures of rat astrocytes , 2000, Journal of neuroscience research.

[79]  C. Bernards,et al.  Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein , 2000, Anesthesiology.

[80]  W. Pardridge,et al.  Brain Microvascular P-Glycoprotein and a Revised Model of Multidrug Resistance in Brain , 2000, Cellular and Molecular Neurobiology.

[81]  F. Holsboer,et al.  Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption , 2000, Neuropsychopharmacology.

[82]  A. Seelig,et al.  Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. , 2000, International journal of clinical pharmacology and therapeutics.

[83]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[84]  D D Breimer,et al.  Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.

[85]  M. Fromm,et al.  P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. , 2000, International journal of clinical pharmacology and therapeutics.

[86]  M. Kool,et al.  The multidrug resistance protein family. , 1999, Biochimica et biophysica acta.

[87]  S. Sisodiya,et al.  Over-expression of P-glycoprotein in malformations of cortical development. , 1999, Neuroreport.

[88]  A. G. de Boer,et al.  The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice , 1999, British journal of pharmacology.

[89]  A. Rabinowicz,et al.  Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. , 1999, Pediatric neurology.

[90]  C. Beglinger,et al.  Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[91]  J. Hellewell,et al.  Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. , 1999, The Journal of clinical psychiatry.

[92]  K. Brouwer,et al.  Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[93]  W. Ong,et al.  Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections , 1999, Experimental Brain Research.

[94]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[95]  G. Regesta,et al.  Clinical aspects and biological bases of drug-resistant epilepsies , 1999, Epilepsy Research.

[96]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[97]  W. Pardridge,et al.  P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries , 1999, Brain Research.

[98]  C. Nemeroff,et al.  Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. , 1998, The Psychiatric clinics of North America.

[99]  R. Vonk,et al.  Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol‐induced cholestasis in the rat , 1998, Hepatology.

[100]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[101]  P. Carvey Drug Action in the Central Nervous System , 1998 .

[102]  U. Bickel,et al.  Brain Microvascular and Astrocyte Localization of P‐Glycoprotein , 1997, Journal of neurochemistry.

[103]  M. Fava,et al.  Definition and epidemiology of treatment-resistant depression. , 1996, The Psychiatric clinics of North America.

[104]  N. Barbaro,et al.  MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy , 1995, Epilepsia.

[105]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[106]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[107]  W. Lasoń [Mechanisms of drug resistance in epilepsy]. , 2006, Przeglad lekarski.

[108]  Jiunn H Lin,et al.  How significant is the role of P-glycoprotein in drug absorption and brain uptake? , 2004, Drugs of today.

[109]  T. Fojo,et al.  Reversal of multidrug resistance: lessons from clinical oncology. , 2002, Novartis Foundation symposium.

[110]  M Thom,et al.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. , 2002, Brain : a journal of neurology.

[111]  G. Scheffer,et al.  Drug resistance molecules: lessons from oncology. , 2002, Novartis Foundation symposium.

[112]  W. Löscher Animal models of drug-resistant epilepsy. , 2002, Novartis Foundation symposium.

[113]  D. Begley,et al.  Drug resistance in epilepsy: the role of the blood-brain barrier. , 2002, Novartis Foundation symposium.

[114]  B. McEwen,et al.  Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.

[115]  W. Pardridge Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.

[116]  J. Silverman Multidrug-resistance transporters. , 1999, Pharmaceutical biotechnology.

[117]  A. Seelig How does P-glycoprotein recognize its substrates? , 1998, International journal of clinical pharmacology and therapeutics.

[118]  R. Duncan,et al.  Epilepsy and the blood-brain barrier. , 1991, British journal of hospital medicine.

[119]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[120]  W. Oldendorf,et al.  Epilepsy and the blood-brain barrier. , 1986, Advances in neurology.